Add to Favorites Newsroom RSS Share
Philadelphia, PA USA

Our News on Newswise

Engineered DNA-encoded PCSK9 Inhibitors May Provide an Effective Alternative for Treating High Cholesterol

Researchers at The Wistar Institute have developed novel synthetic DNA-encoded monoclonal antibodies (DMAbs) directed against PCSK9, a protein key to regulating cholesterol levels in the bloodstream.
5-Dec-2018 3:30 PM EST Add to Favorites

GabrilovichDmitry.jpg

Function of Neutrophils During Tumor Progression Unraveled

Wistar researchers have characterized the function of neutrophils, a type of white blood cells, during early stages of tumor progression, showing that they migrate from the bone marrow to distant sites and facilitate tumor cell seeding and...
15-Oct-2018 8:05 AM EDT Add to Favorites

Synthetic DNA Vaccine Against Ebola Virus Shows Potent and Long-term Efficacy in Preclinical Studies

A novel synthetic DNA vaccine developed based on technology pioneered by Wistar scientists offers complete protection from Zaire Ebolavirus (EBOV) infection in promising preclinical research.
10-Oct-2018 9:10 AM EDT Add to Favorites

Mechanism of Resistance to Novel Targeted Therapy for Ovarian Cancer Identified

Wistar scientists have unraveled a mechanism of resistance to EZH2 inhibitors in ovarian cancers with mutations in the ARID1A gene.
8-Oct-2018 10:05 AM EDT Add to Favorites

Engineered Synthetic DNA-Encoded Checkpoint Inhibitor Antibodies Advance the Field of Cancer Immunotherapy

Wistar scientists and collaborators demonstrate for the first time that through engineering constructs, they can express DNA-encoded monoclonal antibodies (DMAbs) targeting CTLA-4, an important cancer checkpoint molecule that blocks anti-cancer...
4-Oct-2018 10:05 AM EDT Add to Favorites

Targeting Multiple Members of a Family of Tumor Antigens with a Synthetic DNA Vaccine Shows Promise for Cancer Immunotherapy

Wistar scientists have implemented a novel structurally designed synthetic DNA vaccine to simultaneously target multiple members of a family of proteins that are specifically overexpressed in several types of cancer.
27-Sep-2018 11:15 AM EDT Add to Favorites

Virion Therapeutics, LLC Raises $5 Million to Develop Checkpoint Inhibitor Powered Vaccine Therapies for Treatment of Virally Induced Infectious Diseases & Cancers

A new Philadelphia-based start-up, Virion Therapeutics, LLC spun out of The Wistar Institute, will work to advance innovative, immune-based therapies for the treatment of chronic viral-associated cancers and viral infections utilizing the first...
26-Sep-2018 10:05 AM EDT Add to Favorites

Synthetic DNA Vaccine Effective Against Influenza A Virus Subtype That Is Responsible for More Severe Influenza Seasons

Wistar scientists have engineered a synthetic DNA vaccine shown to produce broad immune responses against these H3N2 viruses.
6-Sep-2018 1:15 PM EDT Add to Favorites


see all news

Our YouTube Videos

About

As a nonprofit biomedical research institution, The Wistar Institute is committed to conducting basic research to benefit society and to training the next generation of scientists. Integrity in research is essential to expanding our knowledge of the basic biological processes fundamental to life. All faculty, staff, trainees, and students involved in research at The Wistar Institute are required to maintain the highest standards of ethical conduct in research and to adhere to the rules and regulations of federal agencies governing biomedical research. Faculty and senior research staff are expected to serve as mentors to trainees and students, teaching them the standards of ethical practice in research. Elements of integrity in research include intellectual honesty in conducting and reporting research, maintenance of accurate research records and results, proper allocation of credit among co-authors of studies, fairness in peer review, openness in communications and sharing of resources, transparency in potential conflicts of interest, humane care of animals in the conduct of research, and protection of human subjects in the conduct of research.

Contacts

Darien Sutton
Media Relations & Communications Manager

215-898-3988

Tara Yates
Director of Communications
cancer

215-898-3826

Twitter

Chat now!